PDF herunterladen
CC BY-NC-ND 4.0 · Ibnosina Journal of Medicine and Biomedical Sciences 2021; 13(04): 161-172
DOI: 10.4103/ijmbs.ijmbs_62_21
Review Article

Common complications of hemodialysis: A clinical review

Elmukhtar Habas
1   Department of Medicine, Hamad Medical Corporation, Doha
,
Aml Habas
2   Nephrology Department, Tripoli Pediatric Hospital, Tripoli
,
Mohamed Elgamal
3   Department of Medicine, College of Medicine, Qatar University, Doha
,
Bara Shraim
3   Department of Medicine, College of Medicine, Qatar University, Doha
,
Moaz Moursi
3   Department of Medicine, College of Medicine, Qatar University, Doha
,
Ayman Ibrahim
3   Department of Medicine, College of Medicine, Qatar University, Doha
,
Mohamed Danjuma
1   Department of Medicine, Hamad Medical Corporation, Doha
3   Department of Medicine, College of Medicine, Qatar University, Doha
,
Abdel-Naser Elzouki
1   Department of Medicine, Hamad Medical Corporation, Doha
3   Department of Medicine, College of Medicine, Qatar University, Doha
4   Department of Medicine, Weill Cornell Medical College, Doha
› Institutsangaben
› Weitere Informationen
Auch verfügbar auf
   Lizenzen und Reprints

Long-term hemodialysis (HD) is the main modality used in the treatment of end-stage renal disease (ESRD). It is associated with a variety of complications such as infection, amyloidosis, anemia, undernutrition, as well as musculoskeletal, and cardiovascular system (CVS) morbidities. CVS complications and HD-related infection are the main causes of death in ESRD patients on HD. Other complications such as stroke, disequilibrium syndrome occur during or post-HD. Missing dialysis sessions may lead to amongst others; death due to sudden cardiac arrhythmias; cardiac arrest due to electrolyte disturbance and/or severe overload. This review discusses the common complications of HD as well as recent advances that are likely to impact its outcome.

Key-words:

Amyloidosis - cardiovascular disease - end-stage renal disease - hemodialysis - infection - long-term - renal osteodystrophy - undernutrition

Financial support and sponsorship

Nil.




Publikationsverlauf

Eingereicht: 10. August 2021

Angenommen: 11. August 2021

Artikel online veröffentlicht:
14. Juli 2022

© 2021. The Libyan Authority of Scientific Research and Technologyand the Libyan Biotechnology Research Center. All rights reserved. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License,permitting copying and reproductionso long as the original work is given appropriate credit. Contents may not be used for commercial purposes, oradapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Levey AS, Coresh J. Chronic kidney disease. Lancet 2012;379:165-80.
  • 2 Habas E, Turjman F, Rayani A, Elamour J, Tabib M, El Marghani A, et al. Central bringing excellence in open access SLE nephritis clinical features and renal lesion: Tripoli Central Hospital Experience. J Chronic Dis Manag 2016;1:1006-11.
  • 3 Pozzoni P, Del Vecchio L, Pontoriero G, Di Filippo S, Locatelli F. Long-term outcome in hemodialysis: Morbidity and mortality. J Nephrol 2004;17 Suppl 8:S87-95.
  • 4 GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet 2020;395:709-33.
  • 5 Inker LA, Astor BC, Fox CH, Isakova T, Lash JP, Peralta CA, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. Am J Kidney Dis 2014;63:713-35.
  • 6 Couser WG, Remuzzi G, Mendis S, Tonelli M. The contribution of chronic kidney disease to the global burden of major noncommunicable diseases. Kidney Int 2011;80:1258-70.
  • 7 Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, et al. Chronic kidney disease: Global dimension and perspectives. Lancet 2013;382:260-72.
  • 8 Correa-Rotter R, Wesseling C, Johnson RJ. CKD of unknown origin in Central America: The case for a Mesoamerican nephropathy. Am J Kidney Dis 2014;63:506-20.
  • 9 Gejyo F, Odani S, Yamada T, Honma N, Saito H, Suzuki Y, et al. Beta 2-microglobulin: A new form of amyloid protein associated with chronic hemodialysis. Kidney Int 1986;30:385-90.
  • 10 Vadakedath S, Kandi V. Dialysis: A review of the mechanisms underlying complications in the management of chronic renal failure. Cureus 2017;9:e1603.
  • 11 Prabhakar., Singh RG, Singh S, Rathore SS, Choudhary TA. Spectrum of intradialytic complications during hemodialysis and its management: A single-center experience. Saudi J Kidney Dis Transpl 2015;26:168-72.
  • 12 Liyanage T, Ninomiya T, Jha V, Neal B, Patrice HM, Okpechi I, et al. Worldwide access to treatment for end-stage kidney disease: A systematic review. Lancet 2015;385:1975-82.
  • 13 Himmelfarb J, Ikizler TA. Hemodialysis. N Engl J Med 2010;363:1833-45.
  • 14 Habas EL, Rayani A, Alkanonie W, Habas A, Alzoukie E, Razeik S, et al. Common complications during hemodialysis session; Single central experience. Austin J Nephrol Hypertens 2019;6:1078.
  • 15 Menon S, Munshi R. Blood-borne viral infections in pediatric hemodialysis. Pediatr Nephrol 2019;34:1019-31.
  • 16 Mashragi F, Bernstein RS, Al-Mazroa M, Al-Tawfiq JA, Filemban S, Assiri A, et al. HIV transmission at a Saudi Arabia hemodialysis unit. Clin Infect Dis 2014;59:897-902.
  • 17 Allegranzi B, Bagheri Nejad S, Combescure C, Graafmans W, Attar H, Donaldson L, et al. Burden of endemic health-care-associated infection in developing countries: Systematic review and meta-analysis. Lancet 2011;377:228-41.
  • 18 Muniz-Junqueira MI, Braga Lopes C, Magalhães CA, Schleicher CC, Veiga JP. Acute and chronic influence of hemodialysis according to the membrane used on phagocytic function of neutrophils and monocytes and pro-inflammatory cytokines production in chronic renal failure patients. Life Sci 2005;77:3141-55.
  • 19 Eleftheriadis T, Antoniadi G, Liakopoulos V, Kartsios C, Stefanidis I. Disturbances of acquired immunity in hemodialysis patients. Semin Dial 2007;20:440-51.
  • 20 Kato S, Chmielewski M, Honda H, Pecoits-Filho R, Matsuo S, Yuzawa Y, et al. Aspects of immune dysfunction in end-stage renal disease. Clin J Am Soc Nephrol 2008;3:1526-33.
  • 21 Roubicek C, Brunet P, Huiart L, Thirion X, Leonetti F, Dussol B, et al. Timing of nephrology referral: Influence on mortality and morbidity. Am J Kidney Dis 2000;36:35-41.
  • 22 Fram D, Okuno MF, Taminato M, Ponzio V, Manfredi SR, Grothe C, et al. Risk factors for bloodstream infection in patients at a Brazilian hemodialysis center: A case-control study. BMC Infect Dis 2015;15:158.
  • 23 Eleftheriadis T, Liakopoulos V, Leivaditis K, Antoniadi G, Stefanidis I. Infections in hemodialysis: A concise review. Part II: Blood transmitted viral infections. Hippokratia 2011;15:120-6.
  • 24 Collins AJ, Foley RN, Gilbertson DT, Chen SC. United States Renal Data System public health surveillance of chronic kidney disease and end-stage renal disease. Kidney Int Suppl (2011) 2015;5:2-7.
  • 25 Okuno S, Ishimura E, Kitatani K, Chou H, Nagasue K, Maekawa K, et al. Relationship between parathyroid gland size and responsiveness to maxacalcitol therapy in patients with secondary hyperparathyroidism. Nephrol Dial Transplant 2003;18:2613-21.
  • 26 Alavian SM, Kabir A, Ahmadi AB, Lankarani KB, Shahbabaie MA, Ahmadzad-Asl M. Hepatitis C infection in hemodialysis patients in Iran: A systematic review. Hemodial Int 2010;14:253-62.
  • 27 Elamin S, Abu-Aisha H. Prevention of hepatitis B virus and hepatitis C virus transmission in hemodialysis centers: Review of current international recommendations. Arab J Nephrol Transplant 2011;4:35-47.
  • 28 Ozer Etik D, Ocal S, Boyacioglu AS. Hepatitis C infection in hemodialysis patients: A review. World J Hepatol 2015;7:885-95.
  • 29 World Health O. Global Hepatitis Report 2017: Web Annex B: WHO Estimates of the Prevalence and Incidence of Hepatitis C Virus Infection by WHO Region, 2015. Geneva: World Health Organization, Contract No.: WHO/CDS/HIV/18.46; 2018.
  • 30 Jadoul M, Bieber BA, Martin P, Akiba T, Nwankwo C, Arduino JM, et al. Prevalence, incidence, and risk factors for hepatitis C virus infection in hemodialysis patients. Kidney Int 2019;95:939-47.
  • 31 Marinaki S, Boletis JN, Sakellariou S, Delladetsima IK. Hepatitis C in hemodialysis patients. World J Hepatol 2015;7:548-58.
  • 32 Ali N, Hussain W, Hayat A, Shah T, Wen R, Zeb I, et al. Prevalence and risk factors of hepatitis B and C viruses among haemodialysis patients: A multicentric study. Eur J Gastroenterol Hepatol 2019;31:29-33.
  • 33 Hussain Y, Shahzad A, Azam S, Munawar N. Hepatitis-C and it's seroconversion in end stage kidney disease patients on maintenance hemodialysis and factors affecting it. Pak J Med Sci 2019;35:66-70.
  • 34 Selm SB. Prevalence of hepatitis C virus infection among hemodialysis patients in a single center in Yemen. Saudi J Kidney Dis Transpl 2010;21:1165-8.
  • 35 Eman Gusbi EG, Elzouki I, Alemam H, Musa M, Alhudiri IM, Enattahet N, et al. Prevalence of hepatitis C infection in hemodialysis patients: Report from 37 hemodialysis centers in Libya. Libyan J Med Sci 2019;3:42.
  • 36 Goodkin DA, Bragg-Gresham JL, Koenig KG, Wolfe RA, Akiba T, Andreucci VE, et al. Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: The Dialysis Outcomes and Practice Patterns Study (DOPPS). J Am Soc Nephrol 2003;14:3270-7.
  • 37 Bianco A, Bova F, Nobile CG, Pileggi C, Pavia M, Collaborative Working Group. Healthcare workers and prevention of hepatitis C virus transmission: Exploring knowledge, attitudes and evidence-based practices in hemodialysis units in Italy. BMC Infect Dis 2013;13:76.
  • 38 Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: New estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 2012;30:2212-9.
  • 39 Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: A systematic review of data published between 1965 and 2013. Lancet 2015;386:1546-55.
  • 40 Finelli L, Miller JT, Tokars JI, Alter MJ, Arduino MJ. National surveillance of dialysis-associated diseases in the United States, 2002. Semin Dial 2005;18:52-61.
  • 41 Oguchi H, Miyasaka M, Tokunaga S, Hora K, Ichikawa S, Ochi T, et al. Hepatitis virus infection (HBV and HCV) in eleven Japanese hemodialysis units. Clin Nephrol 1992;38:36-43.
  • 42 Teles SA, Martins RM, Silva SA, Gomes DM, Cardoso DD, Vanderborght BO, et al. Hepatitis B virus infection profile in central Brazilian hemodialysis population. Rev Inst Med Trop Sao Paulo 1998;40:281-6.
  • 43 Ayatollahi J, Jahanabadi S, Sharifyazdi M, Hemayati R, Vakili M, Shahcheraghi SH. The Prevalence of Occult Hepatitis B Virus in the Hemodialysis Patients in Yazd, Iran. Acta Med Iran 2016;54:784-7.
  • 44 Edey M, Barraclough K, Johnson DW. Review article: Hepatitis B and dialysis. Nephrology (Carlton) 2010;15:137-45.
  • 45 Harnett JD, Parfrey PS, Kennedy M, Zeldis JB, Steinman TI, Guttmann RD. The long-term outcome of hepatitis B infection in hemodialysis patients. Am J Kidney Dis 1988;11:210-3.
  • 46 Fabrizi F, Dixit V, Messa P, Martin P. Transmission of hepatitis B virus in dialysis units: A systematic review of reports on outbreaks. Int J Artif Organs 2015;38:1-7.
  • 47 Castro CE, Madariaga MG. Vascular access-related infections in HIV patients undergoing hemodialysis: Case description and literature review. Braz J Infect Dis 2008;12:531-5.
  • 48 Rao TK. Human immunodeficiency virus infection in end-stage renal disease patients. Semin Dial 2003;16:233-44.
  • 49 Tourret J, Tostivint I, du Montcel ST, Bragg-Gresham J, Karie S, Vigneau C, et al. Outcome and prognosis factors in HIV-infected hemodialysis patients. Clin J Am Soc Nephrol 2006;1:1241-7.
  • 50 Husa P, Linhartová A, Nemecek V, Husová L. Hepatitis D. Acta Virol 2005;49:219-25.
  • 51 Ghadir MR, Belbasi M, Heidari A, Sarkeshikian SS, Kabiri A, Ghanooni AH, et al. Prevalence of hepatitis d virus infection among hepatitis B virus infected patients in qom province, center of Iran. Hepat Mon 2012;12:205-8.
  • 52 Aghasadeghi MR, Mohraz M, Bahramali G, Aghakhani A, Banifazl M, Foroughi M, et al. Frequency and genotype of hepatitis D virus infection in patients infected with HIV and those undergoing hemodialysis. Hepat Mon 2013;13:e7481.
  • 53 Le Gal F, Gault E, Ripault MP, Serpaggi J, Trinchet JC, Gordien E, et al. Eighth major clade for hepatitis delta virus. Emerg Infect Dis 2006;12:1447-50.
  • 54 Mohebbi SR, Zali N, Derakhshan F, Tahami A, Mashayekhi R, Amini-Bavil-Olyaee S, et al. Molecular epidemiology of hepatitis delta virus (HDV) in Iran: A preliminary report. J Med Virol 2008;80:2092-9.
  • 55 Chebrolu P, Colombo RE, Baer S, Gallaher TR, Atwater S, Kheda M, et al. Bacteremia in hemodialysis patients with hepatitis C. Am J Med Sci 2015;349:217-21.
  • 56 Samarbaf-Zadeh AR, Makvandi M, Hamadi A, Kaydani GA, Absalan A, Afrough P, et al. Prevalence of hepatitis G virus among hemodialysis and kidney transplant patients in Khuzestan Province, Iran. Jundishapur J Microbiol 2015;8:e20834.
  • 57 Liu JY, Birkmeyer NJ, Sanders JH, Morton JR, Henriques HF, Lahey SJ, et al. Risks of morbidity and mortality in dialysis patients undergoing coronary artery bypass surgery. Northern New England Cardiovascular Disease Study Group. Circulation 2000;102:2973-7.
  • 58 Saran R, Robinson B, Abbott KC, Agodoa LY, Albertus P, Ayanian J, et al. US Renal Data System 2016 Annual Data Report: Epidemiology of Kidney Disease in the United States. Am J Kidney Dis 2017;69:A7-8.
  • 59 Isotalo PA, Halil A, Green M, Tang A, Lach B, Veinot JP. Metastatic calcification of the cardiac conduction system with heart block: An under-reported entity in chronic renal failure patients. J Forensic Sci 2000;45:1335-8.
  • 60 Malyszko J. Mechanism of endothelial dysfunction in chronic kidney disease. Clin Chim Acta 2010;411:1412-20.
  • 61 Eckardt KU, Gillespie IA, Kronenberg F, Richards S, Stenvinkel P, Anker SD, et al. High cardiovascular event rates occur within the first weeks of starting hemodialysis. Kidney Int 2015;88:1117-25.
  • 62 Assa S, Hummel YM, Voors AA, Kuipers J, Westerhuis R, de Jong PE, et al. Hemodialysis-induced regional left ventricular systolic dysfunction: Prevalence, patient and dialysis treatment-related factors, and prognostic significance. Clin J Am Soc Nephrol 2012;7:1615-23.
  • 63 Ekdahl KN, Soveri I, Hilborn J, Fellström B, Nilsson B. Cardiovascular disease in haemodialysis: Role of the intravascular innate immune system. Nat Rev Nephrol 2017;13:285-96.
  • 64 Savage MT, Ferro CJ, Sassano A, Tomson CR. The impact of arteriovenous fistula formation on central hemodynamic pressures in chronic renal failure patients: A prospective study. Am J Kidney Dis 2002;40:753-9.
  • 65 Movilli E, Viola BF, Brunori G, Gaggia P, Camerini C, Zubani R, et al. Long-term effects of arteriovenous fistula closure on echocardiographic functional and structural findings in hemodialysis patients: A prospective study. Am J Kidney Dis 2010;55:682-9.
  • 66 Bourquelot P. Access flow reduction for cardiac failure. J Vasc Access 2016;17 Suppl 1:S60-3.
  • 67 Zoccali C, Tripepi G, Cutrupi S, Pizzini P, Mallamaci F. Low triiodothyronine: A new facet of inflammation in end-stage renal disease. J Am Soc Nephrol 2005;16:2789-95.
  • 68 Sethi D, Hutchison AJ, Cary NR, Brown EA, Curtis JR, Woodrow DF, et al. Macroglossia and amyloidoma of the buttock: Evidence of systemic involvement in dialysis amyloid. Nephron 1990;55:312-5.
  • 69 Lachmann HJ, Goodman HJ, Gilbertson JA, Gallimore JR, Sabin CA, Gillmore JD, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med 2007;356:2361-71.
  • 70 Bataille S, Fernandez C, Zink JV, Brunet P, Berland Y, Burtey S. The case | A hip fracture in a hemodialysis patient. Pathologic right-hip fracture from β2-microglobulin amyloidosis. Kidney Int 2013;83:1211-2.
  • 71 Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med 2003;349:583-96.
  • 72 Jadoul M, Garbar C, Noël H, Sennesael J, Vanholder R, Bernaert P, et al. Histological prevalence of beta 2-microglobulin amyloidosis in hemodialysis: A prospective post-mortem study. Kidney Int 1997;51:1928-32.
  • 73 Koch KM. Dialysis-related amyloidosis. Kidney Int 1992;41:1416-29.
  • 74 Hoshino J, Yamagata K, Nishi S, Nakai S, Masakane I, Iseki K, et al. Significance of the decreased risk of dialysis-related amyloidosis now proven by results from Japanese nationwide surveys in 1998 and 2010. Nephrol Dial Transplant 2016;31:595-602.
  • 75 Schiffl H. Impact of advanced dialysis technology on the prevalence of dialysis-related amyloidosis in long-term maintenance dialysis patients. Hemodial Int 2014;18:136-41.
  • 76 Hartmann J, Fricke H, Schiffl H. Biocompatible membranes preserve residual renal function in patients undergoing regular hemodialysis. Am J Kidney Dis 1997;30:366-73.
  • 77 Davison SN. Pain in hemodialysis patients: Prevalence, cause, severity, and management. Am J Kidney Dis 2003;42:1239-47.
  • 78 Afifi WM, Abo Elsaoud AM, Elgawish MH, Ghorab AM. Musculoskeletal manifestations in end-stage renal disease patients on hemodialysis and relation to parathyroid dysfunction. Saudi J Kidney Dis Transpl 2019;30:68-82.
  • 79 Jevtic V. Imaging of renal osteodystrophy. Eur J Radiol 2003;46:85-95.
  • 80 Limaye V, Frankham A, Disney A, Pile K. Evaluation of hand function in patients undergoing long term haemodialysis. Ann Rheum Dis 2001;60:278-80.
  • 81 Coco M, Rush H. Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis 2000;36:1115-21.
  • 82 Bover J, Ureña P, Brandenburg V, Goldsmith D, Ruiz C, DaSilva I, et al. Adynamic bone disease: From bone to vessels in chronic kidney disease. Semin Nephrol 2014;34:626-40.
  • 83 Murray AM, Seliger S, Lakshminarayan K, Herzog CA, Solid CA. Incidence of stroke before and after dialysis initiation in older patients. J Am Soc Nephrol 2013;24:1166-73.
  • 84 Power A, Chan K, Singh SK, Taube D, Duncan N. Appraising stroke risk in maintenance hemodialysis patients: A large single-center cohort study. Am J Kidney Dis 2012;59:249-57.
  • 85 Alqahtani F, Berzingi CO, Aljohani S, Al Hajji M, Diab A, Alvi M, et al. Temporal trends in the outcomes of dialysis patients admitted with acute ischemic stroke. J Am Heart Assoc 2018;7:e008686.
  • 86 Wang HH, Hung SY, Sung JM, Hung KY, Wang JD. Risk of stroke in long-term dialysis patients compared with the general population. Am J Kidney Dis 2014;63:604-11.
  • 87 Weigert AL, Schafer AI. Uremic bleeding: Pathogenesis and therapy. Am J Med Sci 1998;316:94-104.
  • 88 Chung S, Koh E, Shin S, Whee C. Malnutrition in patients with chronic kidney disease. Open J Intern Med 2012;2:89-99.
  • 89 Rambod M, Bross R, Zitterkoph J, Benner D, Pithia J, Colman S, et al. Association of Malnutrition-Inflammation Score with quality of life and mortality in hemodialysis patients: A 5-year prospective cohort study. Am J Kidney Dis 2009;53:298-309.
  • 90 Kennedy AC, Linton AL, Eaton JC. Urea levels in cerebrospinal fluid after haemodialysis. Lancet 1962;1:410-1.
  • 91 Sitprija V, Holmes JH. Preliminary observations on the change in intracranial pressure and intraocular pressure during hemodialysis. Trans Am Soc Artif Intern Organs 1962;8:300-8.
  • 92 Mistry K. Dialysis disequilibrium syndrome prevention and management. Int J Nephrol Renovasc Dis 2019;12:69-77.